BTIG Research initiated coverage of Apyx Medical with a rating of Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2026 | $6.00 | Neutral → Buy | BTIG Research |
| 12/16/2025 | $6.00 | Buy | Roth Capital |
| 11/14/2025 | Mkt Perform → Mkt Outperform | Citizens JMP | |
| 11/12/2025 | $8.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 10/17/2024 | Neutral | BTIG Research | |
| 7/14/2023 | $8.00 | Overweight | Stephens |
| 5/20/2022 | $12.00 | Buy | Lake Street |
| 8/13/2021 | $12.00 → $14.00 | Market Outperform | JMP Securities |
SD - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), will return to Miami Swim Week with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations. Building on last year's momentum, Apyx Medical has expanded its vision, introducing AYON, the next generation body contouring system designed to bring together the technologies surgeons rely on most into one comprehensiv
CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing Avéli® (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by Renuvion to reduce sk
CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open1. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion). The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4/A - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
BTIG Research upgraded Apyx Medical from Neutral to Buy and set a new price target of $6.00
Roth Capital initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $6.00
Citizens JMP upgraded Apyx Medical from Mkt Perform to Mkt Outperform
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segmentRaised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026. Recent Financial and Operating Highlights: Reported total revenue of $12.5 million in the first quarter of
CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 7th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537.
Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported
SC 13G - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D/A - Apyx Medical Corp (0000719135) (Subject)